An interventional study of Melatonin and Placebo in Stroke and CVA, sponsored by King Edward Medical University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by King Edward Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 333 studies in Stroke with a site in Pakistan — 103 open to participants now, 134 under way, 1 of them phase 3. Stroke · Pakistan.
Among the 333 studies in Stroke with a site in Pakistan, this one is the 12th largest by planned enrollment of the 306 interventional ones that give a count, is one of 53 that started in 2026, is one of 300 with no phase, reaches primary completion later than 130 of the 133 other live ones, and was the 282nd registered.
8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →103 of the 333 studies in Stroke with a site in Pakistan are open now. Recruiting first, the newest first:
Lahore University of Biological and Applied Sciences · Sites in Pakistan
Ages 45–65
Lahore University of Biological and Applied Sciences · Sites in Pakistan
Ages 45–65
Riphah International University · Sites in Pakistan
Ages 40–60
Ibadat International University, Islamabad · Sites in Pakistan
Ages 40+
Kainat Tariq · Sites in Pakistan
Ages 35–75
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
333 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 2 · Phase 4 3
First in 1998; this study’s year is marked. 53 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is above the median of 49 across 6,036 interventional studies indexed under Stroke.
Median enrollment 42 across the 306 interventional studies, 120 across the 27 observational. Of the 176 that completed or were terminated, 2 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 333 have an industry lead sponsor. The 10 most frequent:
King Edward Medical University is the lead sponsor of 84 studies on the registry; 27 are open to participants now.
King Edward Medical University has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
14 of the studies in Stroke with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07937111Ibadat International University, IslamabadCOMPARATIVE ANALYSIS OF DUAL-TASK COGNITIVE-MOTOR TRAINING AND ACTION OBSERVATION THERAPY ON UPPER LIMB FUNCTIONAL RECOVERY AND HAND DEXTERITY IN PATIENTS WITH SUBACUTE STROKE | 2026-11-18 |
| NCT07887191Ibadat International University, IslamabadEffectiveness of Epley Maneuver Versus Semont Maneuver on Dizziness and Balance in Stroke Survivors With Posterior Canal BPPV | 2026-11-30 |
| NCT07887360Ibadat International University, IslamabadEffect of Lower Limb Proprioceptive Neuromuscular Facilitation Combined With Core Stability Training Versus Proprioceptive Neuromuscular Facilitation Alone on Balance and Functional Mobility in Chronic Stroke Survivors | 2026-12-25 |
| NCT07902284Lahore University of Biological and Applied SciencesEffects of Mirror Therapy and Motor Imagery on Upper Limb Motor Functions in Middle Cerebral Artery Stroke | 2026-12-30 |
| NCT07902310Lahore University of Biological and Applied SciencesEffects of Contralateral Gravity Eliminated Gluteus Medius and Ipsilateral Quadratus Lumborum Strengthening on Pelvic Alignment, Balance and Functional Mobility on Subacute Stroke Patients | 2026-12-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 333 studies in Stroke with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute ischemic stroke (AIS) is a leading cause of mortality and disability worldwide, placing a substantial burden on healthcare systems and society.1 Despite intensive advancements in the stroke care, incomplete neurological recovery after stroke is quite common, with many survivors experiencing persistent motor, cognitive, or sensory deficits.2 These long-term impairments significantly affect the quality of life and highlight the need for additional neurorestorative therapies.3,4 The pathophysiology of ischemic stroke involves a complex cascade of events including excitotoxicity, oxidative stress, inflammation, and apoptosis, which contribute to neuronal injury and limit functional recovery.5,6 Current treatment strategies primarily focus on revascularization and supportive care, with limited options available to actively promote neuroprotection and regeneration.7,8 Melatonin, an endogenous neurohormone hormone primarily involved in regulating sleep-wake cycles, has been shown to possess several potential therapeutic properties, including antioxidant, anti-inflammatory, and neuroprotective effects.9 These properties have led to investigate the use of melatonin as an adjunctive treatment for various conditions, including stroke.10,11 However, its potential benefit in recovery of neurological status in patients with acute ischemic stroke remains understudied.12 Pre-clinical studies have demonstrated that melatonin can attenuate ischemia-induced brain injury, reduce infarct size, and improve functional outcomes.13 There is a compelling need to explore novel therapeutic interventions that can target neurological recovery in stroke patients. Exogenous melatonin administration offers a promising avenue for this intervention.14, 15 Preliminary studies have shown that melatonin may protect against acute ischemic stroke by suppressing both inflammatory and oxidative stresses.16 The purpose of this study is to evaluate the effects of exogenous melatonin supplementation on the neurological and functional recovery in patients with acute ischemic stroke, potentially leading to improved clinical outcomes. By addressing this research gap, the study seeks to provide valuable insights into the potential role of melatonin as a therapeutic agent in the management of acute ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dietary Supplement: Melatonin
Other: Placebo
Melatonin 5 mg tablet administered orally once daily, approximately 1 hour before bedtime, for 3 months.
Matching placebo tablet administered orally once daily, approximately 1 hour before bedtime, for 3 months.
Neurological recovery assessed by NIHSS
Neurological recovery assessed by National Institute of Health Stroke Scale (NIHSS) at baseline, end of one month and end of three months. NIHSS measures stroke severity on a scale from 0 to 42 with higher scores indicating greater severity of stroke. A decrease is NIHSS score on sequential assessment would indicate neurological recovery.
Time frame: 3 months
Functional Recovery assessed by MRS
Functional recovery assessed by Modified Rankin Scale (MRS) at baseline, end of one month and end of three months.
Time frame: 3 months
Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.
Of 3,117 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 11 months is below that.
Counting every sponsor, half of 3,261 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Melatonin
King Edward Medical University